Secondary analyses of data from cholinesterase inhibitors (ChEIs) trials in AD have revealed potential benefit or reduced emergence of psychosis, although there is no RCT demonstrating specific benefit of ChEIs in the management of AD psychosis.171 In a study of over 17,000 individuals without prior psychotropic use from the Swedish Dementia Registry Study, use of ChEIs, particularly at higher doses, was associated with a lower likelihood of starting treatment with antipsychotics in patients with AD, but not DLB.184. This evidence concerns the gene BCHE and Alzheimer disease.